Navigation Links
Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera(TM) for Gaucher Disease
Date:10/2/2009

CRANBURY, N.J., Oct. 2 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced preliminary results from its Phase 2 randomized, open-label study to assess the safety, tolerability and preliminary efficacy of its investigational drug, Plicera(TM) (afegostat tartrate), in treatment-naive adult patients with type 1 Gaucher disease. Two dose regimens of Plicera (225 mg three days on/four days off and seven days on/seven days off) were studied during this six month trial. While all patients enrolled experienced an increase in the level of the target enzyme (GCase) as measured in white blood cells, clinically meaningful improvements in key measures of disease were observed in just one of the eighteen patients who completed the study. The preliminary results suggest that treatment with Plicera was generally well tolerated, with no serious adverse events (SAEs) reported. Nineteen subjects were enrolled and 18 subjects completed the study. One subject discontinued treatment because of an adverse event (conjunctivitis-related symptoms).

Once the data are final, the Company plans to further analyze and evaluate the results in collaboration with its partner, Shire Human Genetic Therapies, Inc. (Shire HGT), and, based on this work, will determine the appropriate next steps for the Plicera program. However, based on these preliminary results, the Company does not expect to advance Plicera into Phase 3 development at this time.

John F. Crowley, President and CEO of Amicus, stated, "The preliminary results of this Phase 2 study certainly do not meet our expectations, but we believe they do provide additional insights into the biological activity of Plicera in Gaucher disease and the pharmacological chaperone technology platform. We plan a detailed analysis to ensure we have a complete understanding of the data."


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Amicus Brief Filed with U.S. Supreme Court in Riegel v. Medtronic, Inc.
2. Retail Industry Leaders Association Files Amicus in California Health Care Litigation
3. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference on September 14, 2009
4. Prime Therapeutics Receives TIPPS Certification
5. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
6. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
7. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
8. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
9. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
10. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
11. Prime Therapeutics Announces URAC Accreditation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2015)... IN (PRWEB) , ... August 02, 2015 , ... Back ... cause in a school, however, back packs can wreck havoc on a kid's spine. ... carry their supplies to and from school. Make sure you are aware of how ...
(Date:8/1/2015)... ... August 01, 2015 , ... The condition where veins are ... and women often causing pain and discomfort. Those who spend a lot of time ... Northeast Houston Vein Center is doing what it can to create awareness and provide ...
(Date:8/1/2015)... ... 01, 2015 , ... Brig and Lita Hart, icons of the network marketing ... Healthy Home mission with the HOPE Movement of EvolvHealth. In what has been a ... have agreed to join their missions of purpose together to change the course of ...
(Date:8/1/2015)... , ... August 01, 2015 , ... Lume Wellness creators ... is free to download on the Apple AppStore. , The app is designed ... mood, thus acting as a tool to view personal health and use this information ...
(Date:8/1/2015)... ... ... 19, 2015 Phil Valentine – the Executive Director of Connecticut Community for Addiction Recovery (CCAR) ... Springer Mountain and heading north. Since that day, Phil has hiked over 1400 miles in ... friends and family. He visited CCAR and left an inspirational message to his staff: ...
Breaking Medicine News(10 mins):Health News:Local AlignLife Doctor Donates Time to Check Back Packs 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2
... Market Will Be Driven by Launches, of Disease-Modifying Therapies, According ... ... Resources, WALTHAM, Mass., Sept. 24 Decision ... and,healthcare issues, finds that by 2016 Genentech/Roche,s Lucentis and Eli,Lilly,s ruboxistaurin ...
... Project Pink Campaign Supports Susan G. Komen for the Cure with its ... Celebrity eBay Auction this October, WHAT: Emmy Award-winning journalist and TV ... in Munchkin,s Project Pink Campaign. ... products -- is once again reminding women everywhere "Don,t Duck ...
... the best ways to encourage an individual to ... a personalized approach, according to researchers at Jefferson ... that simple, personalized interventions that guide recipients through ... screening rates in primary care practices. , Ronald ...
... methods significantly raise exam rate, study finds , MONDAY, ... doctors, offices can improve colorectal cancer screening rates, a ... most common kind of cancer and the third leading ... patients don,t experience any symptoms until the disease is ...
... proprietary PhreesiaPad The first free ... DIEGO and NEW YORK, Sept. 24 At ... offer a free patient check-in,solution in the physician,s ... the check-in process, Phreesia delivers fully,interactive relevant health ...
... Meadow Farms world,s first commercial adopter of vaccine ... Bioniche Life,Sciences Inc. (TSX: BNC), a research-based, technology-driven ... E. coli,O157:H7 in cattle has been used for ... Meadow Farms, an Ontario-based producer of premium beef,integrated ...
Cached Medicine News:Health News:Genentech/Roche's Lucentis and Eli Lilly's Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets 2Health News:Cristina Saralegui Joins Celebrities Including Matthew McConaughey, Courteney Cox and Mariska Hargitay to Raise Money for Breast Cancer Research 2Health News:Jefferson researchers find personalized interventions key to improving colon cancer screening rates 2Health News:Doctors' Office Outreach Boosts Colon Cancer Screening 2Health News:Phreesia Launches at DEMOfall 07 2Health News:Phreesia Launches at DEMOfall 07 3Health News:Beef Cattle Vaccinated Against E. coli O157:H7 2Health News:Beef Cattle Vaccinated Against E. coli O157:H7 3
(Date:7/30/2015)... Calif. , July 30, 2015 IRIDEX ... will release its second quarter 2015 financial results after ...   In conjunction with the release, the Company will ... 5:00 p.m. Eastern Time on Thursday, ... the quarter and other business developments. Interested ...
(Date:7/30/2015)...  Unichem Pharmaceuticals ( USA ), Inc. ... 25 mg 1000-count bottle to the consumer level. This ... to the identification of a Clopidogrel tablet found in ... risk associated with mistakenly taking a Clopidogrel tablet instead ... experiencing Clopidogrel,s side effects which include bleeding and/or bruising. ...
(Date:7/30/2015)... -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ) ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics ... notice it received on May 21, 2015 from the ... was below certain of the Exchange,s continued listing standards, ... the NYSE MKT Company Guide, due to the delay ...
Breaking Medicine Technology:IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... SADDLE BROOK, N.J., Jan. 6, 2011 The FDA,s nod ... options they have to address the problems of sexual dysfunction. ... president of Semprae Laboratories, Inc. The announcement of the approval ... of Flibanserin. Dubbed the "pink pill," the female Viagra equivalent, ...
... COVINGTON, Ky., Jan. 6, 2011 Bexion Pharmaceuticals, LLC announced today ... Board of Directors. Dr. Crawford has had a ... academia. Over ten years of his career were spent at the ... roles and culminating in his appointment as FDA Commissioner. ...
Cached Medicine Technology:What About Us? The State of Women's Sexual Health in Question 2Former FDA Commissioner Joins Bexion Pharmaceuticals Board 2
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
We offer small and large pre-gelled Surface Electrodes suitable for EGG or EMG recordings. Surface Electrodes, Skin Preparation and Conductive Cream complete the setup for a EGG study and are essenti...
We offer small and large pre-gelled Surface Electrodes suitable for EGG or EMG recordings. Surface Electrodes, Skin Preparation and Conductive Cream complete the setup for a EGG study and are essenti...
Medicine Products: